Key Points
- BioVie CEO Cuong Do purchased 15,210 shares at an average price of $2.08, investing $31,636.80 and increasing his ownership by 1,676.96% to 16,117 shares.
- BioVie shares opened at $2.16, while the company reported a quarterly loss of $0.70 per share—worse than analysts’ expected loss of $0.52.
- Investor sentiment remains weak: institutional investors own 4.59% of the stock, and the sole tracked analyst rating is “Sell.”
BioVie Inc. (NASDAQ:BIVI - Get Free Report) insider Joseph Palumbo acquired 4,843 shares of the company's stock in a transaction dated Friday, August 28th. The shares were acquired at an average price of $2.16 per share, for a total transaction of $10,460.88. Following the completion of the purchase, the insider owned 6,036 shares of the company's stock, valued at approximately $13,037.76. This represents a 405.95% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
BioVie Stock Down 1.4%
Shares of BIVI stock opened at $2.16 on Friday. The firm has a market cap of $18.25 million, a price-to-earnings ratio of -0.69 and a beta of 0.60. BioVie Inc. has a 52-week low of $0.82 and a 52-week high of $3.79. The company's 50 day moving average is $1.71 and its 200 day moving average is $1.54.
BioVie (NASDAQ:BIVI - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.18).
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on BIVI shares. Wall Street Zen raised BioVie to a "sell" rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a "sell (e+)" rating on shares of BioVie in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of "Sell".
View Our Latest Stock Report on BioVie
Hedge Funds Weigh In On BioVie
Several institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in BioVie in the fourth quarter worth $25,000. NewEdge Advisors LLC lifted its holdings in shares of BioVie by 283.7% during the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company's stock valued at $53,000 after purchasing an additional 40,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of BioVie in the 2nd quarter worth $57,000. Two Sigma Investments LP acquired a new stake in shares of BioVie in the 3rd quarter worth $62,000. Finally, Squarepoint Ops LLC acquired a new stake in BioVie in the third quarter worth about $63,000. 4.59% of the stock is owned by hedge funds and other institutional investors.
About BioVie
(
Get Free Report)
BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company's research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.
The company's lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
